Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
DirectSens is an Austrian biotechnology company that develops highly sensitive and selective biosensors based on its proprietary direct electron transfer (DET) technology. By utilizing specially engineered enzymes, the company's sensors can transfer electrons directly to electrodes without the need for chemical mediators, resulting in superior stability and accuracy. Their product portfolio includes the LactoSens and MaltoSens systems, which are widely used in the food and beverage industry for rapid quality control. Additionally, DirectSens is leveraging its platform to develop next-generation continuous glucose monitoring (CGM) solutions for the medical sector, specifically targeting diabetes management. The company is a spin-off from the University of Natural Resources and Life Sciences (BOKU) in Vienna and is headquartered in Klosterneuburg.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on DirectSens.